Paige Minemyer

HHS is planning an about-face on the long-delayed rule that would set price ceilings and monetary penalties in the 340B program, moving up its start date by several months.

The Trump administration’s plan to bring down prices in Medicare Part B has drawn skepticism, including from providers who helped sink a similar proposal from the Obama White House. 

Prescription drug markets have yet to align with the drive for value-based care in the provider market, and plenty of hurdles stand in the way of that process, experts say. 

The number of payments tied to value-based models continues to grow, but there’s more work to be done to drive providers to take on risk, according to a new report. 

Hospitals’ uncompensated care burden is likely to rise following the repeal of the ACA’s individual mandate, but there are steps providers can take to mitigate the challenges and risks associated with that trend, according to a new report. 

The Trump administration wants drug companies to put their list prices in television ads, but whether that policy is something it can actually enforce remains a major question. 

The Trump administration is planning to force drug companies to include the list price of their products in direct-to-consumer advertising, as part of its ongoing efforts to bring down the cost of drugs. 

President Donald Trump signed into law on Wednesday two bills that would ban so-called “gag clauses” at the pharmacy counter. 

Providers, both long-standing ones and new entrants, are devising ways to better care for seniors, but fee-for-service Medicare stands in the way, experts say. 

Nearly 1,300 providers have signed up to participate in the first wave of CMS’ new voluntary bundled payment program, the agency said.